RZLT
Rezolute, Inc.
Price Chart
Latest Quote
$4.11
+0.29 (+7.59%)
Current Price
| Previous Close | $3.82 |
| Open | $3.80 |
| Day High | $4.14 |
| Day Low | $3.78 |
| Volume | 1,400,113 |
Stock Information
| Shares Outstanding | 96.72M |
| Total Debt | $934K |
| Cash Equivalents | $107.80M |
| Net Income | $-77.59M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $397.53M |
| EPS (TTM) | $-0.75 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $290.66M |
| Income | $-77.59M |
| Book/sh | $1.04 |
| Cash/sh | $1.11 |
| Employees | 58 |
Financial Ratios
| Quick Ratio | 9.44 |
| Current Ratio | 9.68 |
| Debt/Eq | 0.93 |
Returns & Margins
| ROA | -35.32% |
| ROE | -59.04% |
Ownership
| Insider Ownership | 10.04% |
| Institutional Ownership | 98.71% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -8.77 |
| P/B | 3.94 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $9.80 |
Technical Indicators
| SMA20 | $nan |
| SMA50 | $nan |
| SMA200 | $nan |
| RSI | 36.67 |
| ATR | nan |
| Shares Float | 60.77M |
| Short Float | 22.49% |
| Short Ratio | 11.13 |
| Volatility | 0.54 |
| Rel Volume | 0.83 |
Performance History
| Week | nan% |
| Month | nan% |
| Quarter | nan% |
| 6 Months | nan% |
| YTD | nan% |
| Year | nan% |
| 3 Years | nan% |
| 5 Years | nan% |
| 10 Years | nan% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $nan | 1,400,113 |
| 2026-10-26 | $3.82 | 1,543,500 |
| 2026-10-23 | $3.86 | 1,198,100 |
| 2026-10-22 | $3.86 | 1,355,600 |
| 2026-10-21 | $3.70 | 930,000 |
| 2026-10-20 | $3.70 | 1,225,900 |
| 2026-10-19 | $3.70 | 1,778,900 |
| 2026-10-16 | $3.58 | 1,397,900 |
| 2026-10-15 | $3.90 | 2,118,600 |
| 2026-10-14 | $4.23 | 1,693,700 |
| 2026-10-13 | $4.61 | 1,507,700 |
| 2026-10-12 | $4.87 | 1,009,600 |
| 2026-10-09 | $4.87 | 1,872,900 |
| 2026-10-08 | $4.64 | 2,197,700 |
| 2026-10-07 | $4.38 | 1,689,800 |
| 2026-10-06 | $4.32 | 2,191,800 |
| 2026-10-05 | $4.33 | 4,197,500 |
| 2026-10-02 | $4.01 | 1,646,300 |
| 2026-10-01 | $4.07 | 981,200 |
| 2026-09-30 | $4.14 | 1,702,800 |
| 2026-09-29 | $4.09 | 1,517,800 |
| 2026-09-28 | $4.18 | 1,587,600 |
About Rezolute, Inc.
Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
đ° Latest News
No news articles available at the moment. Check back later for updates on RZLT.
Period:
Loading...
Income Statement (Annual)
| Metric | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $82,966,000 | $79,894,000 | $70,423,000 | $55,990,000 |
| Net Non Operating Interest Income Expense | $5,380,000 | $5,482,000 | $4,870,000 | $4,208,000 |
| Operating Expense | $82,966,000 | $79,894,000 | $70,423,000 | $55,990,000 |
| General And Administrative Expense | $29,168,000 | $18,367,000 | $14,680,000 | $12,177,000 |
| Other Income Expense | - | - | $-2,906,000 | $-5,000 |
| Interest Expense | - | - | - | $0 |
| Interest Expense Non Operating | - | - | - | $0 |
| Other Operating Expenses | - | - | - | - |
| Other Non Operating Income Expenses | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-77,586,000 | $-74,412,000 | $-68,459,000 | $-51,787,000 |
| Net Interest Income | $5,380,000 | $5,482,000 | $4,870,000 | $4,208,000 |
| Interest Income | $5,380,000 | $5,482,000 | $4,870,000 | $4,208,000 |
| Normalized Income | $-77,586,000 | $-74,412,000 | $-65,553,000 | $-51,782,000 |
| Net Income From Continuing And Discontinued Operation | $-77,586,000 | $-74,412,000 | $-68,459,000 | $-51,787,000 |
| Total Operating Income As Reported | $-82,966,000 | $-79,894,000 | $-70,423,000 | $-55,990,000 |
| Net Income Common Stockholders | $-77,586,000 | $-74,412,000 | $-68,459,000 | $-51,787,000 |
| Net Income | $-77,586,000 | $-74,412,000 | $-68,459,000 | $-51,787,000 |
| Net Income Including Noncontrolling Interests | $-77,586,000 | $-74,412,000 | $-68,459,000 | $-51,787,000 |
| Net Income Continuous Operations | $-77,586,000 | $-74,412,000 | $-68,459,000 | $-51,787,000 |
| Pretax Income | $-77,586,000 | $-74,412,000 | $-68,459,000 | $-51,787,000 |
| Interest Income Non Operating | $5,380,000 | $5,482,000 | $4,870,000 | $4,208,000 |
| Operating Income | $-82,966,000 | $-79,894,000 | $-70,423,000 | $-55,990,000 |
| Average Dilution Earnings | - | - | - | $0 |
| Special Income Charges | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-0.75 | $-0.98 | $-1.33 | $-1.01 |
| Basic EPS | $-0.75 | $-0.98 | $-1.33 | $-1.01 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-82,935,000 | $-79,863,000 | $-67,481,000 | $-55,955,000 |
| Reconciled Depreciation | $31,000 | $31,000 | $36,000 | $30,000 |
| EBITDA (Bullshit earnings) | $-82,935,000 | $-79,863,000 | $-70,387,000 | $-55,960,000 |
| EBIT | $-82,966,000 | $-79,894,000 | $-70,423,000 | $-55,990,000 |
| Diluted Average Shares | $103,907,114 | $75,999,000 | $51,466,150 | $51,187,000 |
| Basic Average Shares | $103,907,114 | $75,999,000 | $51,466,150 | $51,187,000 |
| Diluted NI Availto Com Stockholders | $-77,586,000 | $-74,412,000 | $-68,459,000 | $-51,787,000 |
| Research And Development | $53,798,000 | $61,527,000 | $55,743,000 | $43,813,000 |
| Selling General And Administration | $29,168,000 | $18,367,000 | $14,680,000 | $12,177,000 |
| Other Gand A | $29,168,000 | $18,367,000 | $14,680,000 | $12,177,000 |
| Total Unusual Items | - | - | $-2,906,000 | $-5,000 |
| Total Unusual Items Excluding Goodwill | - | - | $-2,906,000 | $-5,000 |
| Gain On Sale Of Security | - | - | $-2,906,000 | $-5,000 |
| Other Special Charges | - | - | - | - |
| Salaries And Wages | - | - | - | - |
Fetched: 2026-10-26
Balance Sheet (Annual)
| Metric | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $100,687,000 | $162,127,000 | $121,003,000 | $116,172,000 |
| Total Assets | $112,849,000 | $175,490,000 | $132,737,000 | $123,721,000 |
| Total Non Current Assets | $2,338,000 | $4,345,000 | $4,084,000 | $18,811,000 |
| Other Non Current Assets | $1,528,000 | $2,925,000 | $1,838,000 | $148,000 |
| Current Assets | $110,511,000 | $171,145,000 | $128,653,000 | $104,910,000 |
| Other Current Assets | $2,710,000 | $3,287,000 | $1,779,000 | $3,014,000 |
| Cash Cash Equivalents And Short Term Investments | $107,801,000 | $167,858,000 | $126,874,000 | $101,896,000 |
| Cash And Cash Equivalents | $10,615,000 | $94,107,000 | $70,396,000 | $16,036,000 |
| Cash Equivalents | $6,102,000 | $89,055,000 | $61,249,000 | $9,945,000 |
| Cash Financial | $4,513,000 | $5,052,000 | $9,147,000 | $6,091,000 |
| Investmentin Financial Assets | - | $0 | $263,000 | $16,470,000 |
| Non Current Prepaid Assets | - | - | - | $148,000 |
| Prepaid Assets | - | - | - | $3,014,000 |
| Non Current Deferred Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $934,000 | $1,615,000 | $2,228,000 | $2,478,000 |
| Long Term Debt And Capital Lease Obligation | $276,000 | $983,000 | $1,660,000 | $1,937,000 |
| Current Debt And Capital Lease Obligation | $658,000 | $632,000 | $568,000 | $541,000 |
| Long Term Debt | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $12,162,000 | $13,363,000 | $11,734,000 | $7,549,000 |
| Total Non Current Liabilities Net Minority Interest | $744,000 | $1,451,000 | $2,128,000 | $2,349,000 |
| Derivative Product Liabilities | $468,000 | $468,000 | $468,000 | $412,000 |
| Current Liabilities | $11,418,000 | $11,912,000 | $9,606,000 | $5,200,000 |
| Payables And Accrued Expenses | $8,723,000 | $9,011,000 | $7,226,000 | $3,776,000 |
| Payables | $5,026,000 | $5,809,000 | $4,901,000 | $3,269,000 |
| Accounts Payable | $5,026,000 | $5,809,000 | $4,901,000 | $3,269,000 |
| Tradeand Other Payables Non Current | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $100,687,000 | $162,127,000 | $121,003,000 | $116,172,000 |
| Total Equity Gross Minority Interest | $100,687,000 | $162,127,000 | $121,003,000 | $116,172,000 |
| Stockholders Equity | $100,687,000 | $162,127,000 | $121,003,000 | $116,172,000 |
| Gains Losses Not Affecting Retained Earnings | $-119,000 | $-7,000 | $-79,000 | $-351,000 |
| Other Equity Adjustments | $-119,000 | $-7,000 | $-79,000 | $-351,000 |
| Retained Earnings | $-481,442,000 | $-403,856,000 | $-329,444,000 | $-260,985,000 |
| Other | ||||
| Ordinary Shares Number | $96,405,982 | $86,995,985 | $53,246,000 | $36,827,000 |
| Share Issued | $96,405,982 | $86,995,985 | $53,246,000 | $36,827,000 |
| Tangible Book Value | $100,687,000 | $162,127,000 | $121,003,000 | $116,172,000 |
| Invested Capital | $100,687,000 | $162,127,000 | $121,003,000 | $116,172,000 |
| Working Capital | $99,093,000 | $159,233,000 | $119,047,000 | $99,710,000 |
| Capital Lease Obligations | $934,000 | $1,615,000 | $2,228,000 | $2,478,000 |
| Total Capitalization | $100,687,000 | $162,127,000 | $121,003,000 | $116,172,000 |
| Additional Paid In Capital | $582,152,000 | $565,903,000 | $450,473,000 | $377,471,000 |
| Capital Stock | $96,000 | $87,000 | $53,000 | $37,000 |
| Common Stock | $96,000 | $87,000 | $53,000 | $37,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $276,000 | $983,000 | $1,660,000 | $1,937,000 |
| Current Capital Lease Obligation | $658,000 | $632,000 | $568,000 | $541,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $2,037,000 | $2,269,000 | $1,812,000 | $883,000 |
| Current Accrued Expenses | $3,697,000 | $3,202,000 | $2,325,000 | $507,000 |
| Net PPE | $810,000 | $1,420,000 | $1,983,000 | $2,193,000 |
| Accumulated Depreciation | $-169,000 | $-138,000 | $-107,000 | $-71,000 |
| Gross PPE | $979,000 | $1,558,000 | $2,090,000 | $2,264,000 |
| Machinery Furniture Equipment | $210,000 | $210,000 | $210,000 | $210,000 |
| Buildings And Improvements | $769,000 | $1,348,000 | $1,880,000 | $2,054,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $97,186,000 | $73,751,000 | $56,478,000 | $85,860,000 |
| Investments And Advances | - | $0 | $263,000 | $16,470,000 |
| Held To Maturity Securities | - | $0 | $263,000 | $16,470,000 |
| Other Properties | - | - | - | - |
Fetched: 2026-10-26
Cash Flow Statement (Annual)
| Metric | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-64,635,000 | $-69,075,000 | $-57,368,000 | $-44,634,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-64,635,000 | $-69,075,000 | $-57,368,000 | $-44,481,000 |
| Cash Flow From Continuing Operating Activities | $-64,635,000 | $-69,075,000 | $-57,368,000 | $-44,481,000 |
| Operating Gains Losses | - | - | $2,906,000 | $5,000 |
| Investing Activities | ||||
| Investing Cash Flow | $-21,098,000 | $-14,541,000 | $48,699,000 | $-101,464,000 |
| Cash Flow From Continuing Investing Activities | $-21,098,000 | $-14,541,000 | $48,699,000 | $-101,464,000 |
| Capital Expenditure | - | - | - | $-153,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $86,404,000 | $49,017,000 | $12,330,000 |
| Financing Cash Flow | $2,241,000 | $107,327,000 | $63,029,000 | $11,571,000 |
| Cash Flow From Continuing Financing Activities | $2,241,000 | $107,327,000 | $63,029,000 | $11,571,000 |
| Net Other Financing Charges | $-35,000 | $-1,059,000 | $-318,000 | $-759,000 |
| Net Common Stock Issuance | $0 | $86,404,000 | $49,017,000 | $12,330,000 |
| Common Stock Issuance | $0 | $86,404,000 | $49,017,000 | $12,330,000 |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| Interest Paid Supplemental Data | $0 | $0 | $0 | $0 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $10,615,000 | $94,107,000 | $70,396,000 | $16,036,000 |
| Beginning Cash Position | $94,107,000 | $70,396,000 | $16,036,000 | $150,410,000 |
| Changes In Cash | $-83,492,000 | $23,711,000 | $54,360,000 | $-134,374,000 |
| Proceeds From Stock Option Exercised | $2,276,000 | $21,982,000 | $14,330,000 | $0 |
| Net Investment Purchase And Sale | $-21,098,000 | $-14,541,000 | $48,699,000 | $-101,311,000 |
| Sale Of Investment | $157,083,000 | $113,599,000 | $115,100,000 | $6,000,000 |
| Purchase Of Investment | $-178,181,000 | $-128,140,000 | $-66,401,000 | $-107,311,000 |
| Change In Working Capital | $330,000 | $47,000 | $3,100,000 | $1,021,000 |
| Change In Payables And Accrued Expense | $-1,166,000 | $2,142,000 | $3,229,000 | $2,341,000 |
| Change In Accrued Expense | $-418,000 | $721,000 | $2,146,000 | $205,000 |
| Change In Payable | $-748,000 | $1,421,000 | $1,083,000 | $2,136,000 |
| Change In Account Payable | $-748,000 | $1,421,000 | $1,083,000 | $2,136,000 |
| Change In Prepaid Assets | $1,496,000 | $-2,095,000 | $-129,000 | $-1,320,000 |
| Other Non Cash Items | $579,000 | $532,000 | $526,000 | $352,000 |
| Stock Based Compensation | $14,460,000 | $7,121,000 | $7,360,000 | $7,268,000 |
| Amortization Of Securities | $-2,449,000 | $-2,394,000 | $-2,837,000 | $-1,370,000 |
| Depreciation Amortization Depletion | $31,000 | $31,000 | $36,000 | $30,000 |
| Depreciation And Amortization | $31,000 | $31,000 | $36,000 | $30,000 |
| Depreciation | $31,000 | $31,000 | $36,000 | $30,000 |
| Net Income From Continuing Operations | $-77,586,000 | $-74,412,000 | $-68,459,000 | $-51,787,000 |
| Net PPE Purchase And Sale | - | - | $0 | $-153,000 |
| Purchase Of PPE | - | - | $0 | $-153,000 |
| Gain Loss On Investment Securities | - | - | $2,906,000 | $5,000 |
| Repayment Of Debt | - | - | - | $0 |
| Net Issuance Payments Of Debt | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Payments | - | - | - | $0 |
| Issuance Of Debt | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
| Asset Impairment Charge | - | - | - | - |
Fetched: 2026-10-26